Nuances in Treating NSCLC

Title:

Nuances in Treating NSCLC

Topic: Hematology-Oncology
Relevant Terms: NSCLC
Primary Audience: The intended audience for the activity is medical oncologists, pulmonologists, and other health care professionals involved in the treatment of patients with non-small-cell lung cancer (NSCLC).
Launch Date: 21-Jul-16
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: 21-Jul-17
Curriculum Name: Nuances in Treating NSCLC

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Utilize biomarkers to guide treatment selection to improve outcomes in patients with NSCLC.
  2. Apply efficacy and safety data of new and emerging agents to optimize the treatment of NSCLC.
  3. Recognize potential toxicities associated with new and emerging agents for NSCLC and educate patients about possible adverse effects to improve adherence and quality of life.

    Faculty

    Roy S. Herbst, MD, PhD
    Ensign Professor of Medicine
    Chief of Medical Oncology
    Yale School of Medicine
    Yale Cancer Center
    Smilow Cancer Hospital
    New Haven, CT
    Sarah B. Goldberg, MD, MPH
    Assistant Professor of Medicine (Medical Oncology)
    Yale Cancer Center
    Yale School of Medicine
    New Haven, CT
    Mehmet Altan, MD
    Clinical Instructor in Thoracic Oncology
    Yale Cancer Center
    New Haven, CT
    This activity was reviewed and updated February 8, 2017.
     
    Provider Statement: This continuing medical education activity is provided by
     
    Support Statement: This activity is supported by an educational grant from Genentech, Inc.
     
    Credit Information/Accreditation:
    Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
     
    Credit Designation:
    Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    This enduring material is approved for 1 year from the date of original release, July 21, 2016 to July 20, 2017.
     
    Disclosures:
    In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
     
    Faculty:
    Roy S. Herbst, MD, PhD
    Consulting Fee: AstraZeneca, Genentech/Roche, Merck, Pfizer
    Contracted Research: Genentech, Merck
    Scientific Advisory Boards: Biothera, Diatech, Kolltan
     
    Sarah B. Goldberg, MD, MPH
    Consulting Fee: Clovis Oncology
    Contracted Research: AstraZeneca, Boehringer-Ingelheim
     
    Mehmet Altan, MD
    No relevant financial relationships to disclose.
     
    External Reviewer:
    David Ross Camidge, MD, PhD
    Consulting Fee: Abbvie, Ariad, Array, Celgene, Clovis, Eli Lilly, Novartis, Orion
    Contracted Research: Ariad
    Data Safety Monitoring Board: G1 Therapeutics
     
    Vindico Medical Education staff report the following relationship(s):
    No relevant financial relationships to disclose.
    Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
     
    Overview:
    Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancers and is associated with poor survival rates. However, in recent years personalized therapies based on the histologic and molecular characteristics of the tumor have emerged. Although these advances offer the possibility of improved outcomes for patients, they also present challenges to the community oncologist. In this interactive, case-based program, key issues about the treatment of advanced NSCLC will be reviewed. Expert commentaries will augment the case and offer perspectives on the nuances of the real-world treatment of NSCLC.
     
    How To Participate in this Activity and Obtain CME Credit
    To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 65% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
     
    Unlabeled and Investigational Usage:
    The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
     
    Copyright Statement:
    Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved.
     
    No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
     
    Educational Tools For Your Clinical Practice:
    For downloadable educational resources, visit below.
    For a full list of all the educational tools available through Vindico Medical Education, please visit www.VindicoCME.com/educationaltools
     
    CME Questions? Contact us at: cme@vindicocme.com or 856-994-9400, ext. 504.
     
    Course Viewing Requirements:
     
    Supported Browsers:
    Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
     
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.